Celldex Therapeutics

Yahoo Finance • 25 days ago

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients with chronic spontaneous urticaria... Full story

Yahoo Finance • last month

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conf... Full story

Yahoo Finance • 2 months ago

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma

Company Logo The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIn... Full story

Yahoo Finance • 2 months ago

Celldex stock falls as barzolvolimab fails in EoE despite Cantor's positive view

Investing.com - Celldex Therapeutics (NASDAQ:CLDX), a $1.6 billion market cap biotech company currently trading near $24, reported negative results from its barzolvolimab study in eosinophilic esophagitis (EoE), despite Cantor Fitzgerald... Full story

Yahoo Finance • 2 months ago

Biggest stock movers Wednesday: FUTU, ALC, and more

[Candlestick chart and data of financial market.] tadamichi Stock futures edged lower early Wednesday as investors awaited the release of the Federal Reserve’s July meeting minutes for fresh clues on the path of interest rates. Here are... Full story

Yahoo Finance • 2 months ago

Celldex slides after Barzolvolimab hits target but fails to improve EoE symptoms in phase 2 trial

[Scientist analyze biochemical samples in advanced scientific laboratory. Medical professional use microscope look microbiological developmental of viral. Biotechnology research in science lab.] Celldex Therapeutics (NASDAQ:CLDX [https://... Full story

Yahoo Finance • 2 months ago

These stocks are moving in today's after hours session

After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE... Full story

Yahoo Finance • 2 months ago

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cell... Full story

Yahoo Finance • 2 months ago

Celldex Therapeutics Inc (NASDAQ:CLDX) Q2 2025 Earnings: Revenue Misses, EPS Narrowly Beats Amid Strong Pipeline Progress

CELLDEX THERAPEUTICS INC (NASDAQ:CLDX [https://www.chartmill.com/stock/quote/CLDX]) REPORTS Q2 2025 EARNINGS: REVENUE MISSES ESTIMATES, EPS NARROWLY BEATS EXPECTATIONS Celldex Therapeutics Inc released its second-quarter 2025 financial re... Full story

Yahoo Finance • 2 months ago

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of barzolvolimab dosing... Full story

Yahoo Finance • 3 months ago

Jasper Therapeutics' SWOT analysis: briquilimab stock faces pivotal moment

Jasper Therapeutics, Inc. (NASDAQ:JSPR), a biopharmaceutical company focused on developing treatments for chronic urticaria, stands at a critical juncture as it navigates recent setbacks and prepares for crucial data readouts. With a marke... Full story

Yahoo Finance • 4 months ago

Celldex stock price target maintained at $50 by H.C. Wainwright

H.C. Wainwright reiterated its Buy rating and $50.00 price target on Celldex Therapeutics (NASDAQ:CLDX) following the company’s presentation of 76-week data from its Phase 2 trial of barzolvolimab in chronic spontaneous urticaria (CSU).... Full story

Yahoo Finance • 4 months ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema  in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE)... Full story

Yahoo Finance • 4 months ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE)... Full story

Yahoo Finance • 4 months ago

Jasper Therapeutics' SWOT analysis: briquilimab's potential in CSU stock scrutinized

Jasper Therapeutics (NASDAQ:JSPR), a biopharmaceutical company focused on developing treatments for chronic spontaneous urticaria (CSU) and other mast-cell mediated diseases, has been garnering attention from investors and analysts alike.... Full story

Yahoo Finance • 4 months ago

Celldex Therapeutics' SWOT analysis: barzolvolimab stock shows promise amid challenges

Celldex Therapeutics , Inc. (NASDAQ:CLDX), currently valued at $1.41 billion, has been making waves in the biopharmaceutical industry with its lead candidate, barzolvolimab, a novel treatment for chronic spontaneous urticaria (CSU) and eos... Full story

Yahoo Finance • 4 months ago

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1)KIT related tolerabi... Full story

Yahoo Finance • 4 months ago

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company’s Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held i... Full story

Yahoo Finance • 4 months ago

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors. "We are excited to welcome Denice to the Celldex Board... Full story

Yahoo Finance • 7 months ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45th Annual Health Care Conference on Tu... Full story